| Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the … HM Kantarjian, XG Thomas, A Dmoszynska, A Wierzbowska, G Mazur, ... Journal of clinical oncology 30 (21), 2670, 2012 | 1278 | 2012 |
| Identification of miR-145 and miR-146a as mediators of the 5q–syndrome phenotype DT Starczynowski, F Kuchenbauer, B Argiropoulos, S Sung, R Morin, ... Nature medicine 16 (1), 49-58, 2010 | 815 | 2010 |
| An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma TE Witzig, JM Vose, PL Zinzani, CB Reeder, R Buckstein, JA Polikoff, ... Annals of Oncology 22 (7), 1622-1627, 2011 | 477 | 2011 |
| Luspatercept in patients with lower-risk myelodysplastic syndromes P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ... New England Journal of Medicine 382 (2), 140-151, 2020 | 451 | 2020 |
| Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for … M Crump, J Kuruvilla, S Couban, DA MacDonald, V Kukreti, CT Kouroukis, ... Journal of Clinical Oncology 32 (31), 3490-3496, 2014 | 443 | 2014 |
| Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial DP Steensma, MR Baer, JL Slack, R Buckstein, LA Godley, ... Journal of clinical oncology 27 (23), 3842, 2009 | 440 | 2009 |
| Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial KL Tan, DW Scott, F Hong, BS Kahl, RI Fisher, NL Bartlett, RH Advani, ... Blood, The Journal of the American Society of Hematology 120 (16), 3280-3287, 2012 | 249 | 2012 |
| Tet2 restrains inflammatory gene expression in macrophages AH Cull, B Snetsinger, R Buckstein, RA Wells, MJ Rauh Experimental hematology 55, 56-70. e13, 2017 | 243 | 2017 |
| Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del (5q) myelodysplastic syndromes and ineligible for or … V Santini, A Almeida, A Giagounidis, S Gröpper, A Jonasova, N Vey, ... Journal of Clinical Oncology 34 (25), 2988-2996, 2016 | 237 | 2016 |
| Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic … MA Sekeres, M Othus, AF List, O Odenike, RM Stone, SD Gore, MR Litzow, ... Journal of Clinical Oncology 35 (24), 2745, 2017 | 236 | 2017 |
| Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy KSJ Elenitoba-Johnson, SD Jenson, RT Abbott, RA Palais, SD Bohling, ... Proceedings of the National Academy of Sciences 100 (12), 7259-7264, 2003 | 226 | 2003 |
| Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final … LH Sehn, A Goy, FC Offner, G Martinelli, MD Caballero, O Gadeberg, ... Journal of Clinical Oncology 33 (30), 3467-3474, 2015 | 179 | 2015 |
| An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis SO Abegunde, R Buckstein, RA Wells, MJ Rauh Experimental hematology 59, 60-65, 2018 | 177 | 2018 |
| High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma R Buckstein, RS Kerbel, Y Shaked, R Nayar, C Foden, R Turner, CR Lee, ... Clinical cancer research 12 (17), 5190-5198, 2006 | 162 | 2006 |
| American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults MA Sekeres, G Guyatt, G Abel, S Alibhai, JK Altman, R Buckstein, H Choe, ... Blood advances 4 (15), 3528-3549, 2020 | 146 | 2020 |
| Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma … J Mangel, HA Leitch, JM Connors, R Buckstein, K Imrie, D Spaner, ... Annals of oncology 15 (2), 283-290, 2004 | 128 | 2004 |
| Shiga-Like Toxin-1 Receptor on Human Breast Cancer, Lymphoma, and Myeloma and Absence From CD34+ Hematopoietic Stem Cells: Implications for Ex Vivo … EC LaCasse, MR Bray, B Patterson, WM Lim, S Perampalam, ... Blood, The Journal of the American Society of Hematology 94 (8), 2901-2910, 1999 | 127 | 1999 |
| Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group D Villa, M Crump, T Panzarella, KJ Savage, CL Toze, DA Stewart, ... J Clin Oncol 31 (9), 1164-1171, 2013 | 126 | 2013 |
| Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B‐cell lymphoma treated in the rituximab era … HR Guirguis, MC Cheung, M Mahrous, E Piliotis, N Berinstein, KR Imrie, ... British journal of haematology 159 (1), 39-49, 2012 | 112 | 2012 |
| A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer … M Crump, D Hedley, S Kamel-Reid, B Leber, R Wells, J Brandwein, ... Leukemia & lymphoma 51 (2), 252-260, 2010 | 112 | 2010 |
